September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The German ROP Registry: Association of demographic factors and the requirement for re-treatments of retinopathy of prematurity
Author Affiliations & Notes
  • Johanna Madeleine Walz
    Eye Center, University of Freiburg, Freiburg, Germany
    Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
  • Sebastian Bemme
    Department of Ophthalmology, University Medical Center Göttingen, Göttingen, Germany
  • Daniel Boehringer
    Eye Center, University of Freiburg, Freiburg, Germany
  • Amelie Pielen
    University Eye Hospital, Hannover Medical School, Hannover, Germany
  • Sabine Aisenbrey
    University Eye Hospital, Eberhard-Karl University Tübingen, Tübingen, Germany
    University Eye Hospital, University of Oldenburg, Oldenburg, Germany
  • Helge Breuβ
    Department of Ophthalmology, HELIOS Klinikum Berlin-Buch, Berlin, Germany
  • Anne F Alex
    Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany
  • Lars Wagenfeld
    Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • Susanne Schiedel
    Department of Ophthalmology, Vivantes Klinikum Neukölln , Berlin, Germany
  • Tim U Krohne
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Andreas Stahl
    Eye Center, University of Freiburg, Freiburg, Germany
  • Footnotes
    Commercial Relationships   Johanna Madeleine Walz, Novartis Pharma GmbH (E), Novartis Pharma GmbH (R), Novartis Pharma GmbH (F); Sebastian Bemme, None; Daniel Boehringer, None; Amelie Pielen, Allergan (C), Bayer Healthcare (R), Bayer HealthCare (C), Novartis Pharma GmbH (C), Novartis Pharma GmbH (R); Sabine Aisenbrey, Bayer HealthCare (C), Bayer HealthCare (R), Novartis Pharma GmbH (C), Novartis Pharma GmbH (R); Helge Breuβ, None; Anne Alex, None; Lars Wagenfeld, Alimera Sciences (C), Bayer HealthCare (R), Bayer HealthCare (C), Novartis Pharma GmbH (C); Susanne Schiedel, None; Tim Krohne, Alcon (F), Bayer HealthCare (R), Heidelberg Engineering (R), Novartis Pharma GmbH (F), Novartis Pharma GmbH (C), Novartis Pharma GmbH (R); Andreas Stahl, Bausch & Lomb (C), Boehringer Ingelheim (C), Novartis Pharma GmbH (F), Novartis Pharma GmbH (R), Novartis Pharma GmbH (C), Zeiss (C)
  • Footnotes
    Support  Retina.net, Jackstaedt Foundation, German Retina Society, German Ophthalmological Society
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 6272. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Johanna Madeleine Walz, Sebastian Bemme, Daniel Boehringer, Amelie Pielen, Sabine Aisenbrey, Helge Breuβ, Anne F Alex, Lars Wagenfeld, Susanne Schiedel, Tim U Krohne, Andreas Stahl; The German ROP Registry: Association of demographic factors and the requirement for re-treatments of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6272.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The German ROP Registry collects multicenter data on ROP treatment and epidemiology of treatment-requiring ROP in Germany.

Methods : Nine participating centers entered data from 90 treated infants into a central database. Logistic regression was used to analyze possible associations of demographic and neonatal factors with the need for repeated treatments of ROP. The demographic covariates sex, gestational age (GA), birth weight, and initial neonatal care (internal vs. referred for treatment) were analyzed. Furthermore, the neonatal covariates need for supplemental oxygen and presence of co-morbidities (bacterial sepsis, systemic mycosis, cerebral hemorrhage, necrotizing enterocolitis or persistent ductus arteriosus) were assessed.

Results : One or more re-treatments were necessary in 31 of 177 eyes (18%). In logistic regression analysis, lower birth weight was significantly associated with multiple treatments for ROP (p=0.04). Mean birth weight was 716±261 g in the subgroup with a single treatment vs. 567±113 g in the subgroup with multiple treatments. Every 100 g of additional birth weight reduced the odds for requiring multiple ROP treatments by 4.4%. Similarly, extended oxygen supplementation was significantly associated with multiple treatments for ROP (p=0.03). Mean duration of oxygen supplementation was 49 days in the subgroup with a single treatment vs. 79 days in the subgroup with multiple treatments. Every day of oxygen supplementation increased the odds for requiring multiple ROP treatments by 4.2%.

Conclusions : All included infants required at least one treatment of ROP. Within this cohort, low birth weight and extended oxygen supplementation were significantly associated with an increased risk of requiring multiple treatments for ROP. This information helps to assess individual risk for ROP recurrence following treatment and to schedule follow-up exams.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×